Guardian^™ Connect
Know More, Guess Less

BETTER SELF-MANAGEMENT FOR YOUR PATIENTS
WITH GUARDIAN^™ CONNECT

WHY STAND ALONE CONTINUOUS GLUCOSE MONITORING (CGM)?

SMBGs are frequently performed less often than recommended¹, because of discomfort, fear, pain or lifestyle^2,3
Up to 75% of hyper- and hypoglycaemic episodes can therefore go undetected⁴
Patients may reduce insulin intake out of fear of hypoglycaemia⁵
Real time continuous glucose monitoring (CGM) can further improve glycemic control^1-3 and reduce fear of hypoglycemia^6,7
Endocrinologist associations endorse the benefits of CGM⁸

WHO IS IT FOR?

If your patients use Multiple Daily Injections (MDI) to manage their diabetes, Guardian™ Connect can help you and your patients to stay on top of it all. As we know diabetes can be difficult to manage at times for patients. In these circumstances Guardian™ Connect can make a difference. Patients can check their glucose anywhere, anytime with just one quick look at their mobile phone. Their caregivers can also access the very same information.

WHAT IS GUARDIAN CONNECT?

With Guardian™ Connect patient can track their sensor glucose level and their activities instantly using their iPhone or iPod Touch compatible mobile device.

A quick glimpse at the mobile screen will let them know their current sensor glucose level and where it’s heading. But there’s more. Setting-up low and high alerts is easy so that patient can be alerted if they are heading towards a hypo or hyper.

It is also easy to share patient glucose reading with their family or friends. Care partners can even receive a text message when patient drops below their target range.

THE GUARDIAN^™ CONNECT SYSTEM

The Guardian Connect Components

BENEFITS FOR PATIENTS

24/7 glucose monitoring and trends
Predictive alerts for high and low
Real-time remote monitoring and SMS alerts for care partners

BENEFITS FOR PHYSICIANS

Availability of patient's CGM data
Automatic data upload to Carelink Professional*
Personalized patient's reports

CONNECTIVITY ACROSS DEVICES WITH GUARDIAN^™ CONNECT

References

Hansen, M. V. et al., 2009. Diabetes Research and Clinical Practice, 85(2), 183–88.
Vincze, G., et al., 2004. The Diabetes Educator, 30(1), 112–25.
Fisher, W. et al., 2013. Clinical Diabetes, 31(1), 34–42.
Kaufman, F.R. et al., 2001. Diabetes Care, 24(12), 2030–34.
Fidler, C., et al., 2011. Journal of Medical Economics,14(5), 646-55
Miller et al. ATTD2016. Diabetes Technology & Therapeutics, 18(S1), A27.
Martyn-Nemeth, P. et al., 2015. Journal of Diabetes and its Complications, 30(1), 167–77.
Fonseca VA, et al. Endocrine Practice 2016. DOI.10.4158/EP161392.CS.

* If accounts are linked.For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use.